Medicine · official US FDA label
METHOCARBAMOL ARROW 500 mg
Méthocarbamol (methocarbamol) · comprimé pelliculé
Want to buy it?
Not in stock in our pharmacies right now. Trouver shows when it is back near you. The reservation pages are in French.
This is a US label.
The official US FDA label for methocarbamol (published as METHOCARBAMOL TABLETS), effective August 31, 2026, describes products sold in the United States. The medicine sold in DR Congo may differ in strength, form or approved uses: ask a pharmacist or a doctor.
Prescription medicine: follow the dose prescribed by your doctor.
Official US FDA label for methocarbamol
Data provided by the U.S. Food and Drug Administration (openFDA), unchanged. The full label on DailyMed.
Uses
INDICATIONS AND USAGE Methocarbamol tablets, USP are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. The mode of action of methocarbamol has not been clearly identified, but may be related to its sedative properties. Methocarbamol does not directly relax tense skeletal muscles in man.
Dosage
US dosage, for products sold in the United States. For a medicine bought in DR Congo, follow its box, its leaflet or your pharmacist.
DOSAGE AND ADMINISTRATION Methocarbamol Tablets, USP 500 mg - Adults: Initial dosage: 3 tablets 4 times daily Maintenance dosage: 2 tablets 4 times daily Methocarbamol Tablets, USP 750 mg - Adults: Initial dosage: 2 tablets 4 times daily Maintenance dosage: 1 tablet every 4 hours or 2 tablets 3 times daily Six grams a day are recommended for the first 48 to 72 hours of treatment. (For severe conditions 8 grams a day may be administered). Thereafter, the dosage can usually be reduced to approximately 4 grams a day.
Warnings and precautions
WARNINGS Since methocarbamol may possess a general CNS depressant effect, patients receiving Methocarbamol tablets, should be cautioned about combined effects with alcohol and other CNS depressants. Safe use of methocarbamol tablets has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol. Therefore, methocarbamol tablets should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see PRECAUTIONS, Pregnancy ). Use in Activities Requiring Mental Alertness Methocarbamol may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle. Patients should be cautioned about operating machinery, including automobiles, until they are reasonably certain that methocarbamol therapy does not adversely affect their ability to engage in such activities.
Side effects
ADVERSE REACTIONS Adverse reactions reported coincident with the administration of methocarbamol include: Body as a whole: Anaphylactic reaction, angioneurotic edema, fever, headache Cardiovascular system: Bradycardia, flushing, hypotension, syncope, thrombophlebitis Digestive system: Dyspepsia, jaundice (including cholestatic jaundice), nausea and vomiting Hemic and lymphatic system: Leukopenia Immune system: Hypersensitivity reactions Nervous system: Amnesia, confusion, diplopia, dizziness or lightheadedness, drowsiness, insomnia, mild muscular incoordination, nystagmus, sedation, seizures (including grand mal), vertigo Skin and special senses: Blurred vision, conjunctivitis, nasal congestion, metallic taste, pruritus, rash, Urticaria To report SUSPECTED ADVERSE REACTIONS, contact Granules Pharmaceuticals Inc., at 1-877-770-3183 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Where to find it in DR Congo
Not in stock in our pharmacies right now
Stock changes with every sale. Search by substance: a medicine with the same composition may be available.
Composition
| Substance | Strength | ATC code |
|---|---|---|
| MÉTHOCARBAMOL (methocarbamol) | 500 mg / un comprimé | — |
Sources
- ●Labels: U.S. Food and Drug Administration, openFDA (public domain). Data provided by the U.S. Food and Drug Administration (openFDA), unchanged. DailyMed.
- ●English names of substances: RxNorm, U.S. National Library of Medicine.
- ●Composition: public medicines database of France (BDPM), ANSM, open licence.
Public information, for reference only: it does not replace the advice of a pharmacist or a doctor. Vimpia writes nothing about how to use a medicine and translates nothing: the label is the US FDA's, unchanged; names, composition and authorizations come from the official sources above.